<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35600183</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2049-0801</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine and surgery (2012)</Title>
          <ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>103757</StartPage>
          <MedlinePgn>103757</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">103757</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2022.103757</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Neuromyelitis Optica (NMO; Devic syndrome,1894) is a CNS demyelinating syndrome. Significant proportion of neuromyelitis optica spectrum disorder is associated with Anti AQ4 Ab. The revised diagnostic criteria for neuromyelitis optica spectrum disorder (2015) has been proposed on the basis of Anti AQ4 Ab status. Most of cases reported has been found in females. It presents with multiple remissions. Common features of acute myelitis and optic neuritis seems to be the usual presentation.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">Herein we report a case of a 35-year-old male with longitudinally extending transverse myelitis and Optic Neuritis with confirmation of Anti AQ4 Ab negative status with presentation of bilateral below knee weakness and incontinence of bowel and bladder. It was confirmed by Magnetic Resonance Imaging.</AbstractText>
          <AbstractText Label="CLINICAL DISCUSSION" NlmCategory="UNASSIGNED">Seronegative neuromyelitis optica spectrum disorder recently classified by 2015 diagnostic criteria associated with strict clinical presentations neuroimaging findings and exclusions of differentials. It presents with a poor prognosis particularly in relapsing course.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We report a case of seronegative neuromyelitis optica spectrum disorder. The prognosis of relapsing course is poor. Early diagnosis and immunomodulators are required to decrease chances of recurrence. Further development of diagnostic modalities in seronegative neuromyelitis optica spectrum disorder is required.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khadka</LastName>
            <ForeName>Bibek</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhattarai</LastName>
            <ForeName>Ayush Mohan</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhakal</LastName>
            <ForeName>Bishal</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karki</LastName>
            <ForeName>Abinash</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Shree Birendra Hospital, Chaunni, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acharya</LastName>
            <ForeName>Apshara</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poudel</LastName>
            <ForeName>Raju</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Shree Birendra Hospital, Chaunni, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med Surg (Lond)</MedlineTA>
        <NlmUniqueID>101616869</NlmUniqueID>
        <ISSNLinking>2049-0801</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute myelitis</Keyword>
        <Keyword MajorTopicYN="N">MOG antibody Negative</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="N">Optic neuritis</Keyword>
        <Keyword MajorTopicYN="N">Seronegative NMOSD</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>3</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35600183</ArticleId>
        <ArticleId IdType="pmc">PMC9121270</ArticleId>
        <ArticleId IdType="doi">10.1016/j.amsu.2022.103757</ArticleId>
        <ArticleId IdType="pii">S2049-0801(22)00517-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wingerchuk D., Lennon V., Pittock S., Lucchinetti C., Weinshenker B. Revised diagnostic criteria for neuromyelitis optica. Neurology [Internet] 2006. https://n.neurology.org/content/neurology/66/10/1485.full.pdf Crossref Pubmed Available from: 66, 10, 1485-1489.</Citation>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep 1;6(9):805–815. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11;364(9451):2106–2112. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D., Banwell B., Bennett J., Cabre P., Carroll W., Chitnis T., et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology [Internet] 2015.  cited, Available from: 85, 2, 177-189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729%20Crossref%20Pubmed</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hor J.Y., Asgari N., Nakashima I., Broadley S.A., Leite M.I., Kissani N., Jacob A., Marignier R., Weinshenker B.G., Paul F., Pittock S.J. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front. Neurol. 2020 Jun 26;11:501. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332882</ArticleId>
            <ArticleId IdType="pubmed">32670177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borisow N., Mori M., Kuwabara S., Scheel M., Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front. Neurol. 2018:888. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6206299</ArticleId>
            <ArticleId IdType="pubmed">30405519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lana-Peixoto M.A., Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019 Jun;7(2):4. Crossref Pubmed.</Citation>
        </Reference>
        <Reference>
          <Citation>Papp V., Magyari M., Aktas O., Berger T., Broadley S.A., Cabre P., Jacob A., Kira J.I., Leite M.I., Marignier R., Miyamoto K. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021 Jan 12;96(2):59–77. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7905781</ArticleId>
            <ArticleId IdType="pubmed">33310876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiala C., Rotstein D., Pasic M.D. Pathobiology, diagnosis, and current biomarkers in neuromyelitis optica spectrum disorders. J. Appl.Labo. Med. 2022 Jan;7(1):305–310. Crossref Pubmed.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamid S.H., Whittam D., Mutch K., Linaker S., Solomon T., Das K., Bhojak M., Jacob A. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J. Neurol. 2017 Oct;264(10):2088–2094. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5617862</ArticleId>
            <ArticleId IdType="pubmed">28840314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Hogancamp W.F., O’brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome) Neurology. 1999 Sep 1;53(5):1107–1110. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10496275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato D.K., Lana‐Peixoto M.A., Fujihara K., De Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. Brain Pathol. 2013 Nov;23(6):647–660. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8029254</ArticleId>
            <ArticleId IdType="pubmed">24118482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherman E., Han M.H. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr. Treat. Options Neurol. 2015 Nov;17(11):1–4. (Crossref Pubmed)</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35600183</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2049-0801</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>78</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of medicine and surgery (2012)</Title>
          <ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report.</ArticleTitle>
        <Pagination>
          <StartPage>103757</StartPage>
          <MedlinePgn>103757</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">103757</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2022.103757</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Neuromyelitis Optica (NMO; Devic syndrome,1894) is a CNS demyelinating syndrome. Significant proportion of neuromyelitis optica spectrum disorder is associated with Anti AQ4 Ab. The revised diagnostic criteria for neuromyelitis optica spectrum disorder (2015) has been proposed on the basis of Anti AQ4 Ab status. Most of cases reported has been found in females. It presents with multiple remissions. Common features of acute myelitis and optic neuritis seems to be the usual presentation.</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="UNASSIGNED">Herein we report a case of a 35-year-old male with longitudinally extending transverse myelitis and Optic Neuritis with confirmation of Anti AQ4 Ab negative status with presentation of bilateral below knee weakness and incontinence of bowel and bladder. It was confirmed by Magnetic Resonance Imaging.</AbstractText>
          <AbstractText Label="CLINICAL DISCUSSION" NlmCategory="UNASSIGNED">Seronegative neuromyelitis optica spectrum disorder recently classified by 2015 diagnostic criteria associated with strict clinical presentations neuroimaging findings and exclusions of differentials. It presents with a poor prognosis particularly in relapsing course.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We report a case of seronegative neuromyelitis optica spectrum disorder. The prognosis of relapsing course is poor. Early diagnosis and immunomodulators are required to decrease chances of recurrence. Further development of diagnostic modalities in seronegative neuromyelitis optica spectrum disorder is required.</AbstractText>
          <CopyrightInformation>© 2022 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Khadka</LastName>
            <ForeName>Bibek</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhattarai</LastName>
            <ForeName>Ayush Mohan</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dhakal</LastName>
            <ForeName>Bishal</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karki</LastName>
            <ForeName>Abinash</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Shree Birendra Hospital, Chaunni, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Acharya</LastName>
            <ForeName>Apshara</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Nepalese Army Institute of Health Sciences, Sanobharyang, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Poudel</LastName>
            <ForeName>Raju</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Shree Birendra Hospital, Chaunni, Kathmandu, Nepal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Med Surg (Lond)</MedlineTA>
        <NlmUniqueID>101616869</NlmUniqueID>
        <ISSNLinking>2049-0801</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute myelitis</Keyword>
        <Keyword MajorTopicYN="N">MOG antibody Negative</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis optica</Keyword>
        <Keyword MajorTopicYN="N">Optic neuritis</Keyword>
        <Keyword MajorTopicYN="N">Seronegative NMOSD</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>3</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35600183</ArticleId>
        <ArticleId IdType="pmc">PMC9121270</ArticleId>
        <ArticleId IdType="doi">10.1016/j.amsu.2022.103757</ArticleId>
        <ArticleId IdType="pii">S2049-0801(22)00517-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wingerchuk D., Lennon V., Pittock S., Lucchinetti C., Weinshenker B. Revised diagnostic criteria for neuromyelitis optica. Neurology [Internet] 2006. https://n.neurology.org/content/neurology/66/10/1485.full.pdf Crossref Pubmed Available from: 66, 10, 1485-1489.</Citation>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep 1;6(9):805–815. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11;364(9451):2106–2112. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15589308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D., Banwell B., Bennett J., Cabre P., Carroll W., Chitnis T., et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology [Internet] 2015.  cited, Available from: 85, 2, 177-189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729%20Crossref%20Pubmed</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hor J.Y., Asgari N., Nakashima I., Broadley S.A., Leite M.I., Kissani N., Jacob A., Marignier R., Weinshenker B.G., Paul F., Pittock S.J. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front. Neurol. 2020 Jun 26;11:501. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332882</ArticleId>
            <ArticleId IdType="pubmed">32670177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borisow N., Mori M., Kuwabara S., Scheel M., Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front. Neurol. 2018:888. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6206299</ArticleId>
            <ArticleId IdType="pubmed">30405519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lana-Peixoto M.A., Talim N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomedicines. 2019 Jun;7(2):4. Crossref Pubmed.</Citation>
        </Reference>
        <Reference>
          <Citation>Papp V., Magyari M., Aktas O., Berger T., Broadley S.A., Cabre P., Jacob A., Kira J.I., Leite M.I., Marignier R., Miyamoto K. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology. 2021 Jan 12;96(2):59–77. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7905781</ArticleId>
            <ArticleId IdType="pubmed">33310876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiala C., Rotstein D., Pasic M.D. Pathobiology, diagnosis, and current biomarkers in neuromyelitis optica spectrum disorders. J. Appl.Labo. Med. 2022 Jan;7(1):305–310. Crossref Pubmed.</Citation>
        </Reference>
        <Reference>
          <Citation>Hamid S.H., Whittam D., Mutch K., Linaker S., Solomon T., Das K., Bhojak M., Jacob A. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J. Neurol. 2017 Oct;264(10):2088–2094. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5617862</ArticleId>
            <ArticleId IdType="pubmed">28840314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk D.M., Hogancamp W.F., O’brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome) Neurology. 1999 Sep 1;53(5):1107–1110. (Crossref Pubmed)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10496275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato D.K., Lana‐Peixoto M.A., Fujihara K., De Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. Brain Pathol. 2013 Nov;23(6):647–660. Crossref Pubmed.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8029254</ArticleId>
            <ArticleId IdType="pubmed">24118482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sherman E., Han M.H. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr. Treat. Options Neurol. 2015 Nov;17(11):1–4. (Crossref Pubmed)</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
